Navigation Links
Derma Sciences Obtains Exclusive Worldwide Rights to MEDIHONEY(R)
Date:12/22/2009

PRINCETON, N.J., Dec. 22 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has completed a comprehensive Heads of Agreement with Comvita New Zealand Ltd. (Comvita) of Paengaroa, New Zealand, covering the worldwide licensing rights for MEDIHONEY® professional wound care and skin care products.

The agreement effectively triples the potential market for Derma Sciences' MEDIHONEY® products. The company currently has North & South America rights only, representing about one-third of the total market, and the agreement would give Derma Sciences rights to the remaining 67%. Comvita controls approximately 75% of worldwide Leptospermum (manuka) honey production and are the owner of key intellectual property and patents concerning the use of honey in medical dressings.

The Heads of Agreement calls for the following:

  1. Derma Sciences to have exclusive worldwide rights to manufacture and sell the full range of MEDIHONEY® wound care and skin care products to the professional and medical market worldwide.
  2. Derma Sciences to manufacture the range of MEDIHONEY® products for Comvita to sell to OTC customers.
  3. Comvita to supply medical-grade manuka honey to Derma Sciences.
  4. Derma Sciences to have all IP rights to MEDIHONEY®, including patents involving dressings composed of more than 50% manuka honey.
  5. A joint Research & Development cooperation agreement between Derma Sciences and Comvita.

The agreement also states that Comvita CEO Brett Hewlett will join Derma Science's Board of Directors.


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
2. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
3. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
4. Derma Sciences Files S-1 Registration Statement
5. Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call
6. Orange County Dermatologist Garners Outstanding Results With New Thermage CPT(R)
7. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
8. Derma Sciences Announces Multiple Clinical Presentations of MEDIHONEY(R) at Upcoming Major Wound Care Conference
9. Estrogen Getting Cool Reception From Dermatologists for Mixed Results in Improving Appearance of Skin
10. Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler
11. BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... Jan. 15, 2014 AARP Foundation today announced it has ... suffering from the severe cold weather that has gripped much ... helping those in need; so to support these emergency relief ... to $250,000, which could mean up to $500,000 in aid. ...
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.125 (12.5 cents) per share on the Common ... of record on July 22, 2011. (Logo: ... CVS Caremark is the largest pharmacy health care provider ...
... Reportlinker.com announces that a new market ... Growth Hormone Deficiency Global ... http://www.reportlinker.com/p0567405/Growth-Hormone-Deficiency-Global-Clinical-Trials-Review-Q2-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development Growth ... 2011 Summary ...
Cached Medicine Technology:Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 2Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 3Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 4Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 5Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 6Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 7Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 8Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 9
(Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
(Date:4/17/2014)... days to find a colored ribbon representing a disease. A ... what color ribbon does one think of with lung cancer?, ... many suffering from the disease, black may be the only ... of lung cancer patients, primarily smokers between the ages of ... the stigma often felt by these patients, the emotional toll ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... expert says, , WEDNESDAY, July 22 (HealthDay News) -- When ... kind of snack that matters, but who eats it. , ... women, the healthy-weight women wanted less of the treat over ... non-obese women respond to high-energy, high-density snacks in different ways," ...
... , , IRVINE, Calif., July ... Pulse CO-Oximetry and Measure-Through Motion and Low-Perfusion pulse oximetry, today announced it ... 4, 2009 after the market closes on Tuesday, August 4, 2009. , ... results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will ...
... , , , ... July 22 Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. ... cooperative group-sponsored randomized Phase 2 trial in advanced metastatic breast ... evaluated Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic, ...
... , , BATON ROUGE, ... manage cleanup efforts in hurricane-ravaged areas. Assisting in the diagnosis and ... which one is practically required to live at the gym and work ... careers are both varied and interesting. . .many of them coming with ...
... ... HSA Bank, two innovators in health savings accounts, have announced a new marketing ... easy access to HSA Bank through the My HSA Rewards website to learn ... HSA Bank customers will be given the opportunity to enroll in My HSA ...
... The Centers ... much as 4.5 percent by the year 2010. The additional costs could be passed along ... ... likely increase costs to seniors for their Medicare Advantage health insurance plans, in April the ...
Cached Medicine News:Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 2Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 3Health News:Masimo to Report Second Quarter 2009 Financial Results on August 4, 2009 2Health News:Masimo to Report Second Quarter 2009 Financial Results on August 4, 2009 3Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 2Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 3Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 4Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 5Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 6Health News:MedVance Institute To Offer New High-Demand Courses 2Health News:MedVance Institute To Offer New High-Demand Courses 3Health News:HSA Bank and My HSA Rewards Offer a New Way for HSA Bank Customers to Help Pay for Their Health Care 2Health News:HSA Bank and My HSA Rewards Offer a New Way for HSA Bank Customers to Help Pay for Their Health Care 3Health News:Medicare Agency Announces Decreased Payments to Medicare Advantage Insurers in 2010, Says MedicareSupplementPlans.com 2
... The SurgiGraphic 6000 lets ... tabletop for precise positioning. ... allows for immediate and ... the C-Arm, making it ...
... The REFLEXION 1st MPJ IMPLANT SYSTEM is ... primary reconstruction of the 1st metatarsal phalangeal ... arthritis or revision of a previous arthroplasty. ... three goals: pain relief, superior function and ...
... hands play an important part in our ... and rheumatic changes can cause severe handicaps. ... the finger-joint prostheses was to produce a ... natural function as nearly possible.,The cementless RM ...
... The Low Profile Leg Holder provides precise control ... leg rotation, and maximum exposure of the proximal ... Profile Leg Holder can be used on both ... to different heights.,The Low Profile Leg Holder can ...
Medicine Products: